Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Preclinical efficacy of endoglin-targeting antibody-drug conjugates for the treatment of Ewing sarcoma.

Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordóñez JL, Dominguez-Hormaetxe S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frias MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler KL, Seifert O, Kontermann RE, Pfizenmaier K, Simon L, Fabre M, Carcaboso AM, Ludwig JA, de Álava E.

Clin Cancer Res. 2018 Nov 12. pii: clincanres.0936.2018. doi: 10.1158/1078-0432.CCR-18-0936. [Epub ahead of print]

PMID:
30420447
2.

Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity.

Richter F, Zettlitz KA, Seifert O, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE.

MAbs. 2018 Sep 25:1-12. doi: 10.1080/19420862.2018.1524664. [Epub ahead of print]

PMID:
30252601
3.

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP).

Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, Seifert O.

J Eur Acad Dermatol Venereol. 2018 Sep 22. doi: 10.1111/jdv.15252. [Epub ahead of print]

PMID:
30242921
4.

Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis.

Danielsen K, Duvetorp A, Iversen L, Østergaard M, Seifert O, Tveit KS, Skov L.

Acta Derm Venereol. 2018 Aug 7. doi: 10.2340/00015555-3017. [Epub ahead of print]

5.

IgG-single-chain TRAIL fusion proteins for tumour therapy.

Siegemund M, Schneider F, Hutt M, Seifert O, Müller I, Kulms D, Pfizenmaier K, Kontermann RE.

Sci Rep. 2018 May 17;8(1):7808. doi: 10.1038/s41598-018-24450-8.

6.

Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.

Hutt M, Fellermeier-Kopf S, Seifert O, Schmitt LC, Pfizenmaier K, Kontermann RE.

Oncotarget. 2018 Jan 31;9(13):11322-11335. doi: 10.18632/oncotarget.24379. eCollection 2018 Feb 16.

7.

Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic.

Krasselt M, Baerwald C, Seifert O.

Z Rheumatol. 2018 Oct;77(8):727-734. doi: 10.1007/s00393-017-0410-5.

PMID:
29236153
8.

Significant Changes in the Skin Microbiome in Patients with Chronic Plaque Psoriasis after Treatment with Narrowband Ultraviolet B.

Assarsson M, Duvetorp A, Dienus O, Söderman J, Seifert O.

Acta Derm Venereol. 2018 Apr 16;98(4):428-436. doi: 10.2340/00015555-2859.

9.

Superior Properties of Fc-comprising scTRAIL Fusion Proteins.

Hutt M, Marquardt L, Seifert O, Siegemund M, Müller I, Kulms D, Pfizenmaier K, Kontermann RE.

Mol Cancer Ther. 2017 Dec;16(12):2792-2802. doi: 10.1158/1535-7163.MCT-17-0551. Epub 2017 Sep 13.

10.

Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients.

Thorslund K, Seifert O, Nilzén K, Grönhagen C.

Arch Dermatol Res. 2017 Nov;309(9):721-727. doi: 10.1007/s00403-017-1778-4. Epub 2017 Sep 5.

11.

UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins-TGF-β1-FAP-α.

Wäster P, Orfanidis K, Eriksson I, Rosdahl I, Seifert O, Öllinger K.

Br J Cancer. 2017 Aug 8;117(4):535-544. doi: 10.1038/bjc.2017.182. Epub 2017 Jul 11.

12.

Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.

Schmitt LC, Rau A, Seifert O, Honer J, Hutt M, Schmid S, Zantow J, Hust M, Dübel S, Olayioye MA, Kontermann RE.

MAbs. 2017 Jul;9(5):831-843. doi: 10.1080/19420862.2017.1319023. Epub 2017 Apr 19.

13.

Psoriasis and Pro-angiogenetic Factor CD93: Gene Expression and Association with Gene Polymorphism Suggests a Role in Disease Pathogenesis.

Duvetorp A, Slind Olsen R, Skarstedt M, Söderman J, Seifert O.

Acta Derm Venereol. 2017 Aug 31;97(8):916-921. doi: 10.2340/00015555-2682.

14.

Expression of low-density lipoprotein-related receptors 5 and 6 (LRP5/6) in psoriasis skin.

Duvetorp A, Olsen RS, Nyström H, Skarstedt M, Dienus O, Mrowietz U, Söderman J, Seifert O.

Exp Dermatol. 2017 Nov;26(11):1033-1038. doi: 10.1111/exd.13362. Epub 2017 Jul 9.

PMID:
28418602
15.

Low vaccination rates among patients with rheumatoid arthritis in a German outpatient clinic.

Krasselt M, Ivanov JP, Baerwald C, Seifert O.

Rheumatol Int. 2017 Feb;37(2):229-237. doi: 10.1007/s00296-016-3608-y. Epub 2016 Nov 22.

PMID:
27878345
16.

Bullous Pemphigoid: Validation of the National Patient Register in Two Counties in Sweden, 2001 to 2012.

Grönhagen C, Nilzén K, Seifert O, Thorslund K.

Acta Derm Venereol. 2017 Jan 4;97(1):32-35. doi: 10.2340/00015555-2456.

17.

Transforming Growth Factor Beta Gene Signatures are Spatially Enriched in Keloid Tissue Biopsies and Ex vivo-Cultured Keloid Fibroblasts.

Taylor A, Budd DC, Shih B, Seifert O, Beaton A, Wright T, Dempsey M, Kelly F, Egerton J, Marshall RP, Aston N, Bayat A.

Acta Derm Venereol. 2017 Jan 4;97(1):10-16. doi: 10.2340/00015555-2462.

18.

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

Siegemund M, Seifert O, Zarani M, Džinić T, De Leo V, Göttsch D, Münkel S, Hutt M, Pfizenmaier K, Kontermann RE.

MAbs. 2016 Jul;8(5):879-91. doi: 10.1080/19420862.2016.1172163. Epub 2016 Apr 11.

19.

Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.

Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, Kontermann RE.

MAbs. 2016;8(1):120-8. doi: 10.1080/19420862.2015.1113360.

20.

A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.

Unverdorben F, Hutt M, Seifert O, Kontermann RE.

PLoS One. 2015 Oct 2;10(10):e0139838. doi: 10.1371/journal.pone.0139838. eCollection 2015.

21.

[Pilot Project: Improved Lung Deposition via a New Nasal Inhalation Procedure].

Mursina L, Groß V, Librizzi D, Luster M, Sohrabi A, Seifert O, Hildebrandt O, Heverhagen JT, Koehler U, Sohrabi K.

Pneumologie. 2015 Aug;69(8):469-76. doi: 10.1055/s-0034-1392444. Epub 2015 Aug 10. German.

22.

Immunoliposomes for Targeted Delivery of an Antifibrotic Drug.

Schuster L, Seifert O, Vollmer S, Kontermann RE, Schlosshauer B, Hartmann H.

Mol Pharm. 2015 Sep 8;12(9):3146-57. doi: 10.1021/acs.molpharmaceut.5b00012. Epub 2015 Jul 28.

PMID:
26181293
23.

Telemonitoring and medical care supporting of patients with chronic respiratory diseases.

Sohrabi K, Mursina L, Seifert O, Scholtes M, Hoehle L, Hildebrandt O, Koehler U, Schneider H, Gross V.

Stud Health Technol Inform. 2015;212:141-5.

PMID:
26063269
24.

Tailoring the stealth properties of biocompatible polysaccharide nanocontainers.

Kang B, Okwieka P, Schöttler S, Seifert O, Kontermann RE, Pfizenmaier K, Musyanovych A, Meyer R, Diken M, Sahin U, Mailänder V, Wurm FR, Landfester K.

Biomaterials. 2015 May;49:125-34. doi: 10.1016/j.biomaterials.2015.01.042. Epub 2015 Feb 16.

PMID:
25725561
25.

Increased expression of the Wnt signalling inhibitor Dkk-1 in non-lesional skin and peripheral blood mononuclear cells of patients with plaque psoriasis.

Seifert O, Söderman J, Skarstedt M, Dienus O, Matussek A.

Acta Derm Venereol. 2015 Apr;95(4):407-10. doi: 10.2340/00015555-1970.

26.

Identification and characterization of RNA guanine-quadruplex binding proteins.

von Hacht A, Seifert O, Menger M, Schütze T, Arora A, Konthur Z, Neubauer P, Wagner A, Weise C, Kurreck J.

Nucleic Acids Res. 2014 Jun;42(10):6630-44. doi: 10.1093/nar/gku290. Epub 2014 Apr 25.

27.

Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles.

Seifert O, Pollak N, Nusser A, Steiniger F, Rüger R, Pfizenmaier K, Kontermann RE.

Bioconjug Chem. 2014 May 21;25(5):879-87. doi: 10.1021/bc400517j. Epub 2014 May 7.

PMID:
24766622
28.

Expression and purification of recombinant antibody formats and antibody fusion proteins.

Siegemund M, Richter F, Seifert O, Unverdorben F, Kontermann RE.

Methods Mol Biol. 2014;1131:273-95. doi: 10.1007/978-1-62703-992-5_18.

PMID:
24515473
29.

[Psoriasis is more than just a skin disease. Patients should be monitored for cardiovascular risk factor].

Duvetorp A, Ljungberg A, Seifert O.

Lakartidningen. 2013 Oct 9-15;110(41):1796-8. Review. Swedish. No abstract available.

PMID:
24187892
30.

Tetravalent antibody-scTRAIL fusion proteins with improved properties.

Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE.

Mol Cancer Ther. 2014 Jan;13(1):101-11. doi: 10.1158/1535-7163.MCT-13-0396. Epub 2013 Oct 3.

31.

Gene expression profiling of macrophages: implications for an immunosuppressive effect of dissolucytotic gold ions.

Seifert O, Matussek A, Sjögren F, Geffers R, Anderson CD.

J Inflamm (Lond). 2012 Nov 9;9(1):43. doi: 10.1186/1476-9255-9-43.

32.

The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.

Seifert O, Plappert A, Heidel N, Fellermeier S, Messerschmidt SK, Richter F, Kontermann RE.

Protein Eng Des Sel. 2012 Oct;25(10):603-12. Epub 2012 Sep 17.

PMID:
22988132
33.

Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.

Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, Nussler AK, Göttsch D, Münkel S, Bantel H, Kontermann RE, Pfizenmaier K.

Cell Death Dis. 2012 Apr 12;3:e295. doi: 10.1038/cddis.2012.29.

34.

Ultraviolet exposure of melanoma cells induces fibroblast activation protein-α in fibroblasts: Implications for melanoma invasion.

Wäster P, Rosdahl I, Gilmore BF, Seifert O.

Int J Oncol. 2011 Jul;39(1):193-202. doi: 10.3892/ijo.2011.1002. Epub 2011 Apr 13.

PMID:
21491083
35.

Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option.

Dienus K, Bayat A, Gilmore BF, Seifert O.

Arch Dermatol Res. 2010 Dec;302(10):725-31. doi: 10.1007/s00403-010-1084-x. Epub 2010 Sep 26.

PMID:
20872224
36.

Keloid scarring: new treatments ahead.

Mrowietz U, Seifert O.

Actas Dermosifiliogr. 2009 Dec;100 Suppl 2:75-83. Review.

PMID:
20096165
37.

The skin pathergy test: innately useful?

Varol A, Seifert O, Anderson CD.

Arch Dermatol Res. 2010 Apr;302(3):155-68. doi: 10.1007/s00403-009-1008-9. Epub 2009 Dec 12. Review.

PMID:
20012749
38.

Downregulation of SMAD2, 4 and 6 mRNA and TGFbeta receptor I mRNA in lesional and non-lesional psoriatic skin.

Yu H, Mrowietz U, Seifert O.

Acta Derm Venereol. 2009;89(4):351-6. doi: 10.2340/00015555-0634.

39.

Keloid scarring: bench and bedside.

Seifert O, Mrowietz U.

Arch Dermatol Res. 2009 Apr;301(4):259-72. doi: 10.1007/s00403-009-0952-8. Epub 2009 Apr 10. Review.

PMID:
19360429
40.

Identification of unique gene expression patterns within different lesional sites of keloids.

Seifert O, Bayat A, Geffers R, Dienus K, Buer J, Löfgren S, Matussek A.

Wound Repair Regen. 2008 Mar-Apr;16(2):254-65. doi: 10.1111/j.1524-475X.2007.00343.x. Epub 2008 Feb 13.

PMID:
18282266
41.

Decreased activity of neutrophil glutathione peroxidase in chronic plaque-type psoriasis.

Seifert O, Holmberg J, Linnarsson BM.

J Am Acad Dermatol. 2007 Sep;57(3):528-9. No abstract available.

PMID:
17707156

Supplemental Content

Loading ...
Support Center